These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://keiranjadg146692.getblogs.net/71562276/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide